In addition, navicixizumab (OMP-305B83) is a bispecific antibody that inhibits the Notch pathway and VEGF pathway; Phase 1a trial data showed preliminary signs of anti-tumor activity in multiple tumor types, particularly in ovarian cancer (47). This evidence concerns the gene VEGFA and neoplasm.